At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 478 enrolled
Drug / intervention
Insulin Lispro Low Mixture (LM) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Twice-Daily Insulin Lispro Low Mixture Versus Once-Daily Basal Insulin Glargine and Once-Daily Prandial Insulin Lispro as Insulin Intensification Strategies in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine and Metformin and/or Pioglitazone
In Brief
A Phase 4 clinical trial evaluating Insulin Lispro Low Mixture (LM), Insulin Glargine, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 478 participants across 18 sites in 8 countries.
Detailed Summary
The study is a comparison of twice-daily insulin lispro low mixture versus once-daily basal insulin glargine and once-daily prandial insulin lispro, in participants with Type 2 Diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesArgentina, Brazil, China, Egypt, India, South Korea, Spain, Turkey (Türkiye)
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartApr 2011
Primary CompletionNov 2012
TodayJul 2026
First PostedAug 5, 2010
Enrollment StartApr 1, 2011
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 15.9 years ago
Interventions
Insulin Lispro Low Mixture (LM)drug
Participant-dependent dose, administered subcutaneously for 24 weeks
Insulin Glarginedrug
Participant-dependent dose, administered subcutaneously for 24 weeks
Prandial Insulin Lisprodrug
Participant-dependent dose, administered subcutaneously for 24 weeks